Don Dumont, MD
Pulmonary Disease · Munster, INNPI 1417916073
Payments from drug & device makers
Across 104 payments — averaging $41.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Covidien LP$797
- Johnson & Johnson$570
- Medical Device Business Services, Inc.$390
- GSK$254
- Boehringer Ingelheim$159
- plus $628 from 11 others
What the payments were for
- Travel & lodging$2,20251%
- Food & beverage$2,06748%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $1,483 |
| Covidien LP | 3 | $797 |
| Johnson & Johnson(2 entities) | 13 | $570 |
| Medical Device Business Services, Inc. | 5 | $390 |
| GSK | 27 | $254 |
| Boehringer Ingelheim | 9 | $159 |
| Novartis | 6 | $127 |
| Mylan Specialty L.p. | 6 | $101 |
| Sunovion Pharmaceuticals Inc. | 8 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| AstraZeneca | 4 | $61 |
| Philips North America LLC | 2 | $53 |
| Genentech USA, Inc. | 4 | $48 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Grifols USA, LLC | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,180
- superDimension$778
- Monarch Platform$263
- MONARCH$224
How this compares
$4,280 in reported general payments places this provider in the 60th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $393,215 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 368 | $309,249 |
| Breo ElliptaFluticasone/Vilanterol | 366 | $190,125 |
| Spiriva RespimatTiotropium Bromide | 80 | $70,109 |
| Incruse ElliptaUmeclidinium Bromide | 107 | $47,972 |
| Spiriva HandihalerTiotropium Bromide | 38 | $30,835 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $29,158 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 28 | $25,126 |
| Arnuity ElliptaFluticasone Furoate | 70 | $24,192 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $18,200 |
| DuleraMometasone/Formoterol | 34 | $14,037 |
| XareltoRivaroxaban | 16 | $13,217 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 513 | $12,561 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $10,781 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $9,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $254 | $600,696963 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $159 | $488,450144 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $61 | $21,77466 claims |
| Johnson & JohnsonXarelto | $570 | $13,21716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Munster
- Asaad JandaliMunster$161K
- Fadi LayousMunster$64K
- Bassem SrourMunster$16K
- Wassim ShwaikiMunster$16K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.